Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000665032 | SCV000789087 | uncertain significance | Cystic fibrosis | 2016-12-28 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV001158875 | SCV001320538 | uncertain significance | CFTR-related disorder | 2017-07-15 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Labcorp Genetics |
RCV000665032 | SCV001641318 | likely benign | Cystic fibrosis | 2024-11-03 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000665032 | SCV002620532 | uncertain significance | Cystic fibrosis | 2023-12-04 | criteria provided, single submitter | clinical testing | The c.3874-4A>G intronic variant results from an A to G substitution 4 nucleotides upstream from coding exon 24 in the CFTR gene. This variant was identified in one male with congenital bilateral absence of the vas deferens with the 5T allele in trans (Cheng H et al. J Assist Reprod Genet, 2022 Mar;39:719-728). This nucleotide position is not well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will not have any significant effect on splicing. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |